Dr. Lal Path Labs Ltd. (LALPATHLAB)
Attached
AI summary
- Q1 FY27 revenue 798 Cr +19.1% y-y; EBITDA 247 Cr +28.7% y-y; PAT 170 Cr +27.2% y-y
- Volume growth: samples +10.7%, patients +8.2% in Q1 FY27
- Highest quarterly revenue growth in 4 years; growth driven by organic strength and new tests
- Operating margin improved to 31.0% in Q1 FY27; disciplined execution sustaining profitability
- Rural outreach active in 7 states; 110,000+ patients tested in Q1 FY27
- Strong cash position supports strategic flexibility and inorganic growth
- Geographic revenue spread: Delhi & NCR 31%, UP & UK 19%, East India 15%, West India 14%
- Focus on scientific leadership, patient experience, operational excellence, and AI technology
- Continued investment in R&D and academic partnerships to maintain leadership
- ESG initiatives include solar power, electric bikes, and quality control patent
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 LALPATHLAB — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add LALPATHLAB to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Dr. Lal Path Labs Ltd.
Important.
The summary above is generated automatically from Dr. Lal Path Labs Ltd.'s own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.